Austrian MedTech Biome Diagnostics goes NASDAQ

Biome Diagnostics receives multiple awards for excellence, and advertising space at NASDAQ Tower in Times Square, New York.

Biome Diagnostics, a leading Austrian company in the field of medical microbiome diagnostics, has won several awards for outstanding performance at many internationally renowned events. The awards highlight the company's commitment and innovation in developing groundbreaking oncology and preventive solutions in the microbiome field.

At the EIT Health Catapult Finals, held at the prestigious Bits & Pretzels HealthTech conference in Munich, Biome Diagnostics was awarded 2nd place in the MedTech category. The Austrian MedTech not only won a cash prize but also several industry awards. Furthermore, the audience recognized the company's groundbreaking innovations by rewarding it with the coveted Alex Casta Audience Award. Biome Diagnostics is thus now able to present its logo at the NASDAQ Tower in Times Square in New York, where it is seen by millions of people worldwide.

Biome Diagnostics' international strength was also recognized nationally at the Austrian Chamber of Commerce (WKÖ) Export Day with the "Born Global Champion 2023" Award. This award recognizes the outstanding achievements of Austrian startups that are successful in international markets from their inception, offer innovative products and services, and show rapid growth. Nikolaus Gasche, Co-Founder and Managing Director of Biome Diagnostics, on the successes at Bits & Pretzels HealthTech: "Last week was unique and overwhelming. To be able to perform as a finalist of the EIT Health Catapult in front of thousands of visitors and to reach 2nd place in the process means a lot to us. I would especially like to thank the audience who voted us as the most innovative company and thus awarded us with the Alex Casta Audience Award. It is a special milestone to be able to show Biome Diagnostics in front of millions of people in Times Square, sharing the vision of world-class microbiome diagnostics. This is the only way to advance personalized medicine."

Barbara Sladek, PhD, MBA, Co-Founder and Managing Director of Biome Diagnostics, on the Born Global Champions Award: "We are incredibly proud of the recognition Biome Diagnostics received last week. The Born Global Champions award is a validation of our ongoing efforts to develop innovative microbiome solutions on an international scale that have a positive impact on healthcare. I am very grateful to our supporters and partners for getting us to this point."

Biome Diagnostics GmbH

Founded in 2018, Biome Diagnostics GmbH (BiomeDx) is an Austrian-based medtech company dedicated to advancing precision medicine through breakthrough microbiome-based technologies. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced bioinformatics and machine learning algorithms to develop best-in-class technologies for routine clinical diagnostics. Biome Diagnostics is the only double ISO-certified (ISO 9001 and ISO 13485) microbiome diagnostics company in the world. In 2019, the company launched the successful lifestyle analysis myBioma®, providing easy access to understanding one's gut microbiome. In 2022, the company launched the first medically validated and CE-IVD certified diagnostic test for individualized prediction for response to cancer immunotherapy. This test is the first step in determining the best therapy for a cancer patient. Biome Diagnostics currently has one of the largest datasets of analyzed gut microbiome profiles. The successful start-up has already attracted media attention by winning the audience vote at last year's WebSummit and also the EY ScaleUp Award (for HealthTech), collecting various prizes at this year's European EIT Health Catapult Incubator and, of course, receiving several awards from the WKO, the daily newspaper DiePresse, etc.

For more information, visit

Further inquiry

Nikolaus Gasche
Founder and Managing Director, Biome Diagnostics GmbH
Mobile: +43 1 9974276-99
Email: office(at)

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)